Skip to content

Hassabis AI venture Isomorphic Labs lands $5 billion round

Category
News
Published
Reading time
2 min

Biotech venture Isomorphic Labs, a Google DeepMind offshoot, has secured $5 billion to fund AI-based drug development. It previously brought in $2.1 billion through a round in May 2026.

Isomorphic Labs, the Alphabet-backed venture spun out of Google DeepMind in 2021, said on Nov. 17 it had secured $5 billion in a Series C round. The money will scale its proprietary IsoDDE drug-design engine and expand its pipeline of AI-designed drug candidates.

The round was led by Greenoaks and Sequoia Capital. New investor Andreessen Horowitz joined returning backers Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

It is the company's second round above $1 billion since May 2026, when Isomorphic Labs brought in $2.1 billion through a Series B round.

Isomorphic Labs runs drug-development partnerships with Eli Lilly, Novartis and Johnson & Johnson and reports positive preclinical results, meaning lab and model testing rather than human trials, in oncology and immunology.

Founder and chief executive Demis Hassabis also chairs DeepMind and serves as Alphabet's chief scientist. He stepped down from day-to-day leadership at DeepMind in August 2026. DeepMind director John Jumper, who worked on AlphaFold, shared the 2024 Nobel Prize in Chemistry with Hassabis.

Among the new round's goals is taking the company's AI-designed drug candidates into clinical trials. None of its candidates can become an approved medicine without testing in humans. Isomorphic Labs did not disclose a timeline.